Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

BACKGROUND: Overactive bladder (OAB) is common among older adults. The efficacy and safety of vibegron for the treatment of OAB were demonstrated in the international, phase III EMPOWUR trial. This subpopulation analysis from EMPOWUR assessed the efficacy and safety of vibegron in patients aged ≥ 65...

Descripción completa

Detalles Bibliográficos
Autores principales: Varano, Susann, Staskin, David, Frankel, Jeffrey, Shortino, Denise, Jankowich, Rachael, Mudd, Paul N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882560/
https://www.ncbi.nlm.nih.gov/pubmed/33469832
http://dx.doi.org/10.1007/s40266-020-00829-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882560/
https://www.ncbi.nlm.nih.gov/pubmed/33469832
http://dx.doi.org/10.1007/s40266-020-00829-z

Ejemplares similares